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Background: Investigations of the impact of ethnicity and socio-economic status on incidence and outcomes
of Staphylococcus aureus bacteraemia are limited.
Methods: We prospectively identified all S. aureus bacteraemia episodes in the Australian New Zealand Cooperative
on Outcomes in Staphylococcal Sepsis cohort study between 2007 and 2010. We calculated population level
incidence rates using regional postcodes and stratified the analysis by ethnicity, age and socio-economic status
indexes.
Results: There were 7539 episodes of S. aureus bacteraemia with an annual incidence of 112 episodes per 100,000
population. The age-adjusted incidence in the Indigenous population was 625 per 100,000 population with an age
standardized incidence rate ratio of 59 compared to the non-Indigenous population and an incidence rate ratio of
29.2 for community-associated methicillin-resistant S. aureus (MRSA). Populations in the lowest socio-economic
status quintile had an increased S. aureus bacteraemia incidence compared to higher quintiles. However, there was
a disparity between Indigenous and non-Indigenous populations across all socio-economic status quintiles. The
lower 30-day mortality for Indigenous patients (7%) compared to non-Indigenous patients (17%) was explained by
differences in age.
Conclusions: Indigenous Australians suffer from a higher rate of S. aureus bacteraemia than non-Indigenous
Australians, particularly for community-associated MRSA. Ethnicity and socio-economic status had little impact
on subsequent mortality, with other host factors contributing more significantly.
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Ethnicity or race can influence the incidence and out-
comes of infectious diseases. Compared to Caucasians,
African-Americans and native Americans are 21 and 59
times more likely to acquire pneumococcal bacteremia
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reproduction in any medium, provided the orpandemic, Australian Indigenous populations were at
increased risk of hospitalization [2]. In Staphylococcus
aureus infections, African-Americans have an increased
risk of acquiring community-associated methicillin-re-
sistant S. aureus (MRSA) infections compared to Cauca-
sians [3,4]. Similarly, bacteremia is more common in
certain ethnic groups [5]. In Australia, Indigenous popu-
lations suffer from S. aureus bacteraemia (SAB) at rates
significantly higher than non-Indigenous Australians in
both northern and Central Australia [6-8].
Likewise, socio-economic status (SES) is known to im-
pact infectious diseases rates through differences intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cess to and use of washing and sanitation facilities, differ-
ences in comorbidities such as smoking, hazardous
alcohol use and diabetes, access to health care facilities
and differing health seeking behaviour. Previous studies
have found lower income households [5] and those living
in public housing complexes [4] to be at higher risk of
acquiring community-associated MRSA infections or
MRSA post-operative wound infections [9]; and com-
pared to lower SES strata, SAB occurred significantly less
frequently in higher SES strata [10]. Similarly, the preva-
lence of the dominant community-associated MRSA
lineage in the United States (US), USA300 MRSA, is
influenced by SES with the mean income of high preva-
lence neighbourhoods approximately US $15000 per
annum less than low prevalence suburbs [11]. In Austra-
lia, a correlation between lower SES and the incidence of
staphylococcal infections has been observed [7].
In contrast to the incidence of infections due to patho-
gens such as S. aureus, there is no consistent evidence
that mortality is associated with SES. Although, a higher
mortality due to sepsis has been detected in resource
limited countries compared to wealthier countries, these
data may be explained by differences in hospital access
or care as opposed to SES [12]. In Central Australia,
there were no differences between Indigenous and non-
Indigenous patients in short term mortality; however,
mortality for the subset of Indigenous patients present-
ing with more than one episode of blood stream infec-
tion was markedly increased [6]. Indigenous status was
not found to be associated with survival using multivari-
ate analysis in one study of SAB in Australia. However,
this study included only a small number of Indigenous
patients (n=53) [13]. In a recent study of sepsis from
tropical northern Australia where S. aureus was the
most common pathogen (25%), there was no significant
difference in 28-day mortality rates between Indigenous
and non-Indigenous patients, with multivariate analysis
showing age to be a strong predictor of mortality [14].
Therefore, it remains unclear what contribution ethnicity
per se makes to incidences and outcomes of SAB as ethni-
city and SES are frequently interlinked. For example, in
Australia and the United States, many Indigenous people
live in remote communities or reservations where both
poverty and remoteness impact on health and healthcare
access. In addition, SES is a difficult variable to study as it
is seldom collected or recorded in health studies. The aim
of this study was to determine the impact of ethnicity and
SES on the incidence and outcomes of SAB in a large
nation-wide dataset of cases of SAB in Australia.
Methods
All SAB episodes were prospectively identified from
institutions participating in the Australian New ZealandCooperative on Outcomes in Staphylococcal Sepsis [13]
study between 2007 and 2010. Data were collected for
each episode and included age, sex, postcode (zipcode
equivalent), ethnicity, date of admission, date of dis-
charge, principal diagnosis and principal antibiotic used
for management and overall 30-day mortality. All data
were entered through a web-based collection system
with each anonymized entry uniquely identified at the
participating institution to allow for follow-up and cor-
rection of discrepant results by regular audits.
Isolates were categorised into methicillin-susceptible
S. aureus (MSSA) and MRSA episodes by their sus-
ceptibility pattern. MRSA was further characterized
into probable community-associated MRSA (cMRSA) –
resistant to ≤2 non-β-lactam antibiotics; and probable
epidemic MRSA (eMRSA) comprising multi-resistant
MRSA – resistant to ≥2 non-B-lactam antibiotics,
and probable United Kingdom epidemic MRSA type 15
(E-MRSA 15) – resistant to ≤2 non-B-lactam antibiotics
but resistant to ciprofloxacin ± erythromycin.
An episode of SAB was defined as a single positive
blood culture bottle for S. aureus in a patient that had
symptoms and signs consistent with an infection. A new
episode in the same patient was recorded if the bacter-
aemia had cleared, but a further blood culture taken
greater than 14 days after the initial positive culture was
again positive. SAB episodes occurring ≥48 and <48
hours after hospital admission were considered nosoco-
mial and community-onset bacteremias respectively.
Community-onset episodes were deemed healthcare-
associated if patients had ≥1 of the following healthcare-
associated risk factors in the previous 12 months:
hospitalisation, surgery, residency in a long term care
facility or receipt of renal dialysis.
Denominator data were acquired from the Australian
Bureau of Statistics (ABS) based on the 2006 census.
Ethnicity, age and socio-economic indexes for area
(SEIFA) were extracted by postcode [15]. The specific
SEIFA index used was the “Index of Relative Socio-
economic Advantage and Disadvantage” (IRSAD) which
is a relative score constructed from data on income, edu-
cational level, employment status, occupation type,
housing status, internet access, disability status, car own-
ership, and single parenthood status of a specific post-
code compared to all other postcodes [15]. Indigenous
status is not a variable used in the construction of the
IRSAD. Deciles of the IRSAD, as provided and suggested
for use by the ABS, were used for analysis. A lower
IRSAD decile compared to a higher decile indicates a
lower SES. Only SAB episodes occurring in postcodes
represented in the ABS dataset were included in the ana-
lysis. Data collection was considered complete for the
entire period for all institutions to calculate SAB
incidences.
Figure 1 S. aureus bacteremia incidence rates by age and
ethnicity. Incidence rates are stratified by age comparing
non-Indigenous (white columns) with Indigenous (grey columns)
populations. The bars represent 95% confidence intervals calculated
using a Poisson distribution. The “Total” column represents indirect
age standardized incident rates.
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(StatCorp, Texas, USA). Incidence rates and confidence
intervals were calculated using the Poisson distribution.
The Indigenous population was standardized against the
non-Indigenous population age distribution using indir-
ect methods and age standardized incidence rates with
95% confidence intervals were reported. For analysis of
categorical and continuous data we used χ2, Fisher’s
exact, analysis of variance, Student’s t-test and the
Mann–Whitney U test as appropriate. A multivariate lo-
gistic regression model with 30-day mortality as the in-
dependent outcome was built with the initial inclusion
of variables with a P<02 on univariate analysis and
backwards stepwise elimination of variables using a like-
lihood ratio test to determine the statistical significance
of candidate explanatory variables.
Ethics
Approval to prospectively collect data was provided by
the ethics committee of each participating institution:
Australian Capital Territory – Canberra Hospital; New
South Wales – Blacktown Hospital, Mount Druitt Hos-
pital, Concord Hospital, John Hunter Hospital, Liverpool
Hospital, Nepean Hospital, Royal North Shore Hospital,
St Vincent’s Hospital, Westmead Hospital; Northern Ter-
ritory – Royal Darwin Hospital, Alice Springs Hospital;
Queensland – Ipswich Hospital, Princess Alexandra
Hospital, Royal Brisbane and Women’s Hospital; South
Australia – Royal Adelaide Hospital, Flinders Medical
Centre, Women’s and Children’s Hospital; Tasmania –
Royal Hobart Hospital; Victoria – The Alfred Hospital,
Austin Health, Monash Medical Centre, Western Health;
Western Australia – Fremantle Hospital, Royal Perth
Hospital. Consent from each patient was not required as
the collection of data was considered to be a clinical audit.
Results
Population level incidence of S. aureus bacteremia
There were 7633 SAB episodes identified from 24 par-
ticipating institutions in Australia over the four years
2007–2010 from the Australian New Zealand Coopera-
tive on Outcomes in Staphylococcal Sepsis study. 94
(1%) episodes were excluded as postcodes were incom-
plete or not represented in the 2006 Australian census.
The proportion of Indigenous cases in the included
dataset (536/7539 [7.1%]) was similar to that for the en-
tire dataset (536/7633 [6.5%]). The final 7539 episodes
for analysis occurred in an annualised population of
16,842,651 represented by 1258 postcodes from all States
and Territories of Australia and comprising a non-
Indigenous population of 16,453,420 and an Indigenous
population of 389,230. The overall crude annual inci-
dence was 112 (95% confidence [CI] 10.9, 115) SAB
episodes per 100,000 population. There were 1256deaths and an overall crude annual mortality rate of 19
(95% CI 18, 20) deaths per 100,000 population.
There were 7003 non-Indigenous episodes and 536
Indigenous episodes. The crude non-Indigenous annual
incidence was 106 and the age standardized Indigenous
annual incidence was 625 per 100,000 population with
an age standardized incidence rate ratio (IRR) of 59
(95% CI 54, 64) for Indigenous compared to non-
Indigenous rates. Indigenous incidences were higher
across all age strata except for those aged 80–89 and
90+ years (Figure 1). Notably, the peak incidence was
in the 40–59 year old age groups for the Indigenous
population, which was a markedly different pattern
compared to the non-Indigenous population where inci-
dence steadily increased with age. There were 1219
non-Indigenous deaths and 37 Indigenous deaths with
an age standardized mortality ratio of 39 (95% CI 28,
54) for Indigenous compared to non-Indigenous rates.
We compared annual incidence rates stratified by SES
as recorded by postcode using the “Index of Relative
Socio-economic Advantage and Disadvantage” (IRSAD).
This demonstrated that those in the lowest IRSAD quin-
tile (i.e., lowest SES quintile) had a higher incidence than
those in the upper four IRSAD quintiles (Figure 2)
(P<0001). To investigate if SES explained the differences
in incidence rates of SAB between non-Indigenous and
Indigenous populations we calculated age standardized
incidence rates stratified by IRSAD quintiles (Figure 3).
The overall pattern of higher incidence in the lowest
IRSAD quintile was replicated when the non-Indigenous
population alone was examined (Figure 3) (P<0001).
The numbers of cases within the quintiles for the Indi-
genous population were 227, 29, 77, 149 and 54 for
Figure 2 S. aureus bacteremia incidence rates by Index of
Relative Socio-economic Advantage and Disadvantage
quintiles. The bars represent 95% confidence intervals calculated
using a Poisson distribution.
Figure 4 S. aureus bacteremia incidence rates stratified by
susceptibility pattern and ethnicity. Comparisons are between
non-Indigenous (white columns) with Indigenous (grey columns)
populations. Indirect age standardized incident rates with 95%
confidence intervals are reported. MSSA, methicillin-susceptible S.
aureus; cMRSA, community-associated methicillin-resistant S. aureus;
eMRSA, epidemic MRSA.
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trend in incidence across IRSAD quintiles for the Indi-
genous population. However, the differences between
non-Indigenous and Indigenous populations existed
across all IRSAD quintiles with age standardized IRRs
ranging from 19 to 8.5 for Indigenous compared to
non-Indigenous rates.
We also compared age standardized IRRs for MSSA,
cMRSA and eMRSA between non-Indigenous and Indi-
genous populations. Although the incidence rates were
significantly higher for Indigenous populations for all
three groups of S. aureus (Figure 4), this was most
marked for cMRSA (IRR 29.2 [95% CI 24, 35]) compared
to MSSA (IRR 52 [95% CI 47, 57]) and eMRSA (IRRFigure 3 S. aureus bacteremia incidence rates by Index of
Relative Socio-economic Advantage and Disadvantage quintiles
and ethnicity. Comparisons are between non-Indigenous (white
columns) and Indigenous (grey columns) populations. Indirect age
standardized incidence rates with 95% confidence intervals are
reported.23 [95% CI 15, 33]) when comparing Indigenous to
non-Indigenous rates.
Ethnic differences for those with S. aureus bacteremia
We conducted a more detailed analysis of the 7539 epi-
sodes of SAB to investigate differences due to ethnicity.
Of these episodes, the ethnic background was noted to
be Indigenous for 536, Asian for 318, Caucasian for
6,346, Polynesian for 123, and ‘Other’ for 216. On uni-
variate analysis, there were significant differences in age,
IRSAD score, place of acquisition, receipt of dialysis, pri-
mary focus of infection, intensive care unit (ICU) admis-
sion, and mortality (Table 1). In particular, the 30-day
mortality for Indigenous patients of 7% (37/536) was sig-
nificantly less than that for non-Indigenous patients of
17% (1219/7003). In addition, a far greater proportion of
SAB were due to cMRSA in the Indigenous (129/536,
24%) patients compared to other ethnicities (458/7003,
7%) (Figure 5). Indigenous patients also had the lowest
mean IRSAD of all ethnic groups.
Predictors of mortality
Given the significant difference in 30-day mortality be-
tween Indigenous and non-Indigenous groups we looked
for independent predictors of mortality on multivariate
analysis. Independent predictors of mortality were age,
healthcare-associated acquisition, the primary focus of
infection, admission to ICU and the antibiotic treatment
received (Table 2). Of note, neither ethnicity, SES using
the IRSAD, nor the isolate susceptibility profile were in-
dependently associated with mortality. Thus, differences
in mortality across the ethnicities are principally deter-
mined by the differences in age distributions of patients
Table 1 Comparison of characteristics of S. aureus bacteremia across ethnic populations
Indigenous (n=536) Asian (n=318) Caucasian (n=6346) Polynesian (n=123) Other (n=216) P
Demographic traits
Age (median) 44 55 65 48 58 <0.001a
Age (mean) 40 (20) 52 (25) 61 (23) 43 (22) 51 (25) <0.001b
Sex (Male) 321 (60) 206 (65) 4179 (66) 80 (65) 144 (67) 0.09
IRSAD (mean) 4.6 (3.2) 6.9 (3.0) 6.7 (2.7) 4.7 (2.8) 6.3 (2.7) <0.001c
Acquistion <0.001d
CO 154 (29) 58 (19) 1235 (20) 23 (21) 33 (16)
CO HCA 243 (46) 104 (34) 2517 (42) 48 (43) 86 (42)
Nosocomial 131 (25) 141 (47) 2306 (38) 40 (36) 85 (42)
Risk factors
Dialysis 139 (26) 44 (14) 541 (9) 25 (20) 34 (16) <0.001
IDU 30 (6) 17 (7) 369 (8) 5 (7) 11 (8) 0.86e
Device related 162 (32) 130 (43) 2145 (36) 39 (34) 80 (39) 0.02f
Primary focus
Endocarditis 20 (4) 19 (6) 378 (6) 5 (4) 11 (5) 0.25
Bone/joint 91 (17) 40 (13) 782 (12) 21 (17) 22 (10) 0.01
SSTI 128 (24) 57 (18) 1152 (18) 27 (22) 51 (24) 0.005
Outcomes
ICU 91 (17) 43 (14) 763 (12) 19 (15) 19 (9) 0.004
Mortality 7 days 15 (3) 24 (8) 636 (10) 8 (7) 9 (4) <0.001
Mortality 30 days 37 (7) 49 (17) 1135 (19) 12 (12) 23 (12) <0.001g
Note. Data are number (%) of patients and means (standard deviations). IRSAD, Index of Relative Socio-economic Advantage or Disadvantage; CO,
community-onset; HCA, healthcare-associated; IDU, intravenous drug using; SSTI, skin and soft tissue infection; ICU, intensive care unit.
a Kruskal-Wallis test; b Analysis of variance test (F=123.7, df=4); c Analysis of variance test (F=89.3, df=4); d χ2 test for 3x5 table. Missing data for Indigenous – 8,
Asian – 15, Caucasian – 288, Polynesian – 12, Other – 12; e Missing data for Indigenous – 54, Asian – 75, Caucasian – 1474, Polynesian - 48, Other – 71; f Missing
data for Indigenous – 23, Asian – 14, Caucasian – 370, Polynesian – 8, Other – 12; g Missing data for Indigenous – 17, Asian – 30, Caucasian – 415, Polynesian – 19,
Other – 19.
Figure 5 The proportional distribution of susceptibility patterns
of S. aureus bacteremia for different ethnicities. MSSA,
methicillin-susceptible S. aureus; cMRSA, community-associated
methicillin-resistant S. aureus; eMRSA, epidemic MRSA.
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by comparisons of mean and median ages (Table 1) and
histograms of age (data not shown).Discussion
In analysing an Australia wide dataset of 7539 episodes
of SAB we found a disturbingly large disparity in the
population incidence of SAB between the non-
Indigenous and Indigenous populations of Australia with
an age-adjusted incidence rate ratio of 59 for Indigenous
compared to non-Indigenous populations. Increased in-
cidence of SAB according to ethnicity has previously
been noted [7,8,16-18], however, this study is unique in
the size of the disparity observed and the finding that the
disparity is particularly marked for community-associated
MRSA. There are key public health implications arising
from these findings regarding strategies to prevent
staphylococcal infections in Indigenous communities.
Although focused on MRSA, previous studies have
shown high rates of staphylococcal skin and soft tissue
Table 2 Multivariate analysis of variables associated with mortality in patients with S. aureus bacteremia
Variable Unadjusted Adjusted
OR (95% CI) P OR (95% CI) P
Demographic characteristics
Age
0-9 4.2 (1.7, 10.3) 0.002 5.1 (1.7, 15.3) 0.004
10-19 1.3 (0.4, 4.3) 0.682 2.4 (0.6, 10.0) 0.213
20-29 (reference) 1.0 1.0
30-39 2.4 (1.0, 6.0) 0.059 2.7 (0.9, 8.4) 0.078
40-49 4.8 (2.1, 11.2) <0.001 7.1 (2.5, 19.9) <0.001
50-59 7.1 (3.1, 16.4) <0.001 8.5 (3.1, 23.6) <0.001
60-69 10.6 (4.7, 24.1) <0.001 14.8 (5.4, 40.6) <0.001
70-79 18.8 (8.3, 42.6) <0.001 23.8 (8.7, 65.1) <0.001
80-89 29.3 (12.9, 66.3) <0.001 38.1 (13.9, 104) <0.001
90+ 46.2 (19.8, 108) <0.001 54.4 (19.1, 154) <0.001
Sex
Female 1.0
Male 1.0 (0.9, 1.2) 0.838
Ethnicity
Indigenous 1.0
Asian 2.7 (1.7, 4.2) <0.001
Caucasian 3.1 (2.2, 4.3) <0.001
Polynesian 1.7 (0.9, 3.4) 0.131
Other 1.7 (1.0, 3.0) 0.052
IRSAD quintile
1 1.0
2 1.3 (1.0, 1.7) 0.033
3 1.3 (1.0, 1.6) 0.050
4 1.2 (1.0, 1.5) 0.091
5 1.3 (1.0, 1.6) 0.026
Risk factors and Acquisition
Dialysis
No 1.0
Yes 0.7 (0.5, 0.8) <0.001
IDU
No 1.0
Yes 0.3 (0.2, 0.4) <0.001
Acquisition
Community onset 1.0
Community onset HCA 2.1 (1.7, 2.5) <0.001 1.4 (1.1,1.7) 0.011
Nosocomial 2.4 (2.0, 2.9) <0.001 1.5 (1.2,1.9) 0.001
Microbiology and antibiotics
Susceptibility
MSSA 1.0
cMRSA 1.3 (1.0, 1.6) 0.025
eMRSA 2.0 (1.7, 2.3) <0.001
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Table 2 Multivariate analysis of variables associated with mortality in patients with S. aureus bacteremia (Continued)
Antibiotic treatment
β-lactam 1.0
Glycopeptide 2.0 (1.7, 2.3) <0.001 1.5 (1.3, 1.8) <0.001
Other 2.1 (1.6, 2.8) <0.001 1.6 (1.2, 2.2) 0.002
Clinical infection
Primary focus
SSTI 1.0 1.0
Device with 2° infection 1.8 (1.2, 2.7) 0.003 1.9 (1.3, 2.9) 0.003
Device with no 2° infection 0.8 (0.7, 1.0) 0.118 0.9 (0.7, 1.2) 0.600
IE Left sided 1.5 (1.0, 2.1) 0.025 2.2 (1.5, 3.2) <0.001
IE Right sided 0.6 (0.3, 1.1) 0.092 1.4 (0.7, 3.0) 0.308
No focus 1.9 (1.6, 2.4) <0.001 1.4 (1.1, 1.9) 0.011
Bone/joint 0.6 (0.4, 0.8) <0.001 0.8 (0.6, 1.1) 0.228
Respiratory 3.7 (2.9, 4.8) <0.001 3.6 (2.7, 4.8) <0.001
Sepsis 4.4 (3.5, 5.5) <0.001 4.0 (3.1, 5.3) <0.001
ICU
No 1.0 1.0
Yes 1.8 (1.5, 2.1) <0.001 2.2 (1.8, 2.7) <0.001
Note. Adjusted odds ratios and P values are only displayed if that variable was significant in the final multivariate model. OR, odds ratio; CI, confidence interval;
IRSAD, Index of Relative Socio-economic Advantage or Disadvantage; HCA, healthcare-associated; MSSA, methicillin-susceptible S. aureus; cMRSA, community-
associated methicillin-resistant S. aureus; eMRSA, epidemic MRSA; SSTI, skin and soft tissue infection; IE, infective endocarditis; ICU, intensive care unit.
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the world [20]. In Australian Indigenous populations,
the high burden of staphylococcal skin disease appears
to translate directly to higher rates of SAB. Risk factors
are highly prevalent for community-associated S. aureus
infections in Indigenous communities [19] and include
those typically quoted for community-associated MRSA
such as close skin-to-skin contact, openings in the skin
such as cuts or abrasions, contaminated items and sur-
faces, crowded living conditions, and poor hygiene (the
five Cs) (http://www.cdc.gov/mrsa/riskfactors/index.html).
Australian Indigenous remote households are often
crowded (mean of 32 people per bedroom) [21] with in-
adequate facilities for personal hygiene [22]. There are
high rates of skin infections with approximately 70% of
children in remote communities presenting to the local
health clinic with scabies infestation and impetigo by the
age of one year [23]. Such findings are mirrored in other
Indigenous populations [24].
Concomitant with the prevalence of these risk factors
in Indigenous communities, and therefore the likely
widespread use of antibiotics, we noted a considerably
larger incidence rate ratio for Indigenous compared to
non-Indigenous populations for cMRSA bacteremia (IRR
29.2), as contrasted with MSSA (IRR 52) and eMRSA
(IRR 23). This finding is supportive of a previous hy-
pothesis that community-associated MRSA may be
emerging from within, and subsequently spreadingoutside of, Indigenous populations [19]. Previous studies
have also noted an increased risk for MRSA infections
[25] and bacteraemia [26] in Indigenous patients. Pre-
vention of staphylococcal infections in general and
community-associated MRSA specifically will thus re-
quire a multifaceted approach that includes education
about the five Cs as knowledge and awareness of hygiene
remains poor [27]. In addition, addressing issues of
housing and disadvantage is critical in limiting the
spread of community-associated MRSA [21,27]. In the
meantime, there is emerging evidence to suggest that re-
gional community health provider based initiatives in In-
digenous communities can be successful in reducing
scabies and skin infections [28] and that the use of
trimethoprim-sulfamethoxazole rather than benzathine
penicillin to treat impetigo, which is typically caused by
both streptococci and staphylococci in these settings, is
a promising approach in regions with high rates of
community-associated MRSA [29].
For the overall dataset and also the large subset of the
non-Indigenous population from across Australia with
7003 episodes of SAB, there was a higher SAB incidence
in the lowest IRSAD quintile compared to the higher
IRSAD quintiles. This is in agreement with a recent ana-
lysis of S. aureus from the tropical north of Australia
where there was a strong correlation between incident
isolation of S. aureus and measures of both regional
socioeconomic disadvantage and remoteness [7]. There
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SAB incidence across IRSAD quintiles, but when we
compared non-Indigenous and Indigenous populations
stratified by IRSAD quintiles, significant disparities con-
tinued to be present between the ethnic groups across
all IRSAD quintiles. It remains unclear what determines
this ethnic disparity and particularly whether unmeas-
ured aspects of ethnicity and socioeconomic status may
contribute to this increased risk. The lack of a pattern
across IRSAD quintiles within the Indigenous population
may also suggest problems with the IRSAD measure or
inaccuracies due to the relatively small sample size
within some of the quintiles. Nevertheless, it is likely
that the IRSAD score, even at the finest of level of
postcode (with a 2006 estimated average population of
7993 ± 10510), fails to reflect aspects of the social disad-
vantage of many Indigenous communities, particularly
in the sparsely populated regions of northern and
Central Australia where the majority of the Indigenous
cases came from. Indeed, the component factors for the
IRSAD and other measures of SES sought in census sur-
veys do not reflect the risk factors for staphylococcal
skin infections. In particular, the impact of household
crowding, the lack of running water and personal hy-
giene facilities and the impact of remote disadvantage
are not well captured.
Although the incidence of SAB in the Indigenous
population was higher, once diagnosed with SAB, Indi-
genous patients had a surprisingly lower mortality rate
than non-Indigenous populations on univariate analysis.
This is most likely explained by the fact that Indigenous
patients acquired their SAB at a younger age than non-
Indigenous patients. This is supported by a recent study
of sepsis in tropical northern Australia, where incidences
of sepsis and severe sepsis were much higher for Indi-
genous patients, but there was no difference in mortality
rates, with age and living in residential care being the
major predictors for mortality [14]. Notably, SES was
not significantly associated with mortality for either In-
digenous or non-Indigenous patients.
There are several limitations to this study. First, for
calculation of incidence rates we assumed that all epi-
sodes from postcodes included in the study have been
captured. This is unlikely to be the case, particularly as
not all hospitals servicing these postcodes participated in
the study. Thus the reported incidence rates are likely to
underestimate the true incidence. However, this should
not significantly impact upon the key finding of a rela-
tive increased incidence in the Indigenous population.
Second, no data on comorbidities was collected and this
is likely to impact upon mortality. An indication of this
is that the presence of healthcare-associated risk factors
was found to be independently associated with mortality
and may be acting as a proxy for comorbidities. Therewas also missing data for some variables (such as for in-
jection drug use) as presented in Table 1. Third, we were
not able to assess the potential role of host genetic fac-
tors [30] in relation to both incidence and mortality.
Fourth, as noted already use of postcodes for SES ana-
lysis may well have masked real SES differences between
Indigenous and non-Indigenous patients, especially for
some locations with particularly high rates of SAB in In-
digenous patients [66]. It is possible that inclusion of
such details would further explain the disparity in inci-
dence rates between the Indigenous and non-Indigenous
populations. Additionally, there is likely to be significant
heterogeneity in SES within postcodes and future studies
should consider accounting for such heterogeneity by
collecting SES data on an individual case level. Finally,
the categorization of MRSA by antibiogram into prob-
able cMRSA and probable eMRSA is not as accurate as
using genotyping techniques such as spa, multilocus se-
quence or SCCmec typing and may have resulted in
some cases of misclassification.
Conclusions
Our prospective study identified more than 7500 SAB epi-
sodes occurring in population of 16,453,420 resulting in a
crude annual incidence of 112 episodes per 100,000 popu-
lation. Overall Indigenous Australians were 59 times more
likely to have a SAB, especially community-associated
MRSA episodes (29.2 times) compared to non-Indigenous
Australians. Populations in the lowest SES quintile had
an increased SAB incidence compared to higher quin-
tiles. However, there remained a disparity between Indi-
genous and non-Indigenous populations across all SES
quintiles. Thus our study provides robust evidence that
Indigenous populations and lower SES populations are at
increased risk of SAB. Furthermore, standard measures
of SES do not explain the disparity in rates between Indi-
genous and non-Indigenous populations.
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